Inventiva ADRs Rise 22% After Licensing Deal With Chia Tai-Tianqing Pharma
22 Septembre 2022 - 04:38PM
Dow Jones News
By Chris Wack
Inventiva SA ADRs were up 22% to $4.78 after the company said it
signed a licensing and collaboration agreement with Chia
Tai-Tianqing Pharmaceutical Group Co. to develop and commercialize
lanifibranor, Inventiva's proprietary compound for the treatment of
non-alcoholic steatohepatitis and potentially other metabolic
diseases in mainland China, Hong Kong, Macau and Taiwan.
In exchange for receiving an exclusive license to develop,
import, manufacture, commercialize and market lanifibranor in
greater China, Chia Tai-Tianqing, a subsidiary of Sino Biopharm,
will pay Inventiva an upfront payment of $12 million, and $5
million in the short-term if certain clinical milestones are
met.
Under the terms of the agreement, Inventiva has the potential to
receive up to $290 million of clinical, regulatory and commercial
milestone payments. Inventiva also will receive tiered royalties
from high single-digit to mid-teen double digits of net sales made
by Sino Biopharm in greater China during the first three years of
commercialization and from low to mid-teen double digits starting
from year four.
Chia Tai-Tianqing will bear all costs associated with the trials
conducted in greater China.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 22, 2022 10:23 ET (14:23 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Inventiva (EU:IVA)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Inventiva (EU:IVA)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024